Evommune filed to go public, targeting roughly $150 million in an IPO priced between $15 and $17 per share to advance its two phase‑2 clinical assets. The proceeds will support EVO756, an oral MRGPRX2 antagonist being tested in chronic spontaneous urticaria and atopic dermatitis, and EVO301, an IL‑18 pathway neutralizer. Management cited encouraging early data—93% clinical responses in a small CSU cohort at four weeks—and intends to use IPO proceeds for late‑stage trials and corporate growth. The company noted potential timing sensitivities tied to the federal review process amid a government shutdown. The IPO underscores renewed openness in public markets for mid‑stage immunology companies presenting differentiated oral and fusion‑protein approaches to inflammatory skin disease.